IDEXX Laboratories (IDXX) to Release Earnings on Tuesday

IDEXX Laboratories (NASDAQ:IDXX) is scheduled to announce its earnings results before the market opens on Tuesday, August 6th. Analysts expect the company to announce earnings of $2.87 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $468.63 on Monday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. The company has a market capitalization of $38.70 billion, a PE ratio of 45.37, a price-to-earnings-growth ratio of 3.91 and a beta of 1.32. IDEXX Laboratories has a 52-week low of $372.50 and a 52-week high of $583.39. The company has a 50-day simple moving average of $489.02 and a 200 day simple moving average of $514.82.

Insiders Place Their Bets

In related news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 2.11% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

IDXX has been the subject of several research analyst reports. Barclays lowered their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. Finally, BTIG Research initiated coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $582.88.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.